Free tool
FAERS Monitor: Brukinsa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213217 or its brand name (Brukinsa, Zanubrutinib). Reports on generic versions are filed under their own applications.
Reports
4,539
Serious
3,384
75% of reports
Hospitalization
1,174
Death reported
505
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use585
- disease progression318
- myelosuppression254
- fatigue249
- anaemia247
- white blood cell count decreased247
- contusion241
- platelet count decreased219
- rash212
- death211
- pneumonia201
- diarrhoea185
- nausea156
- drug ineffective155
- asthenia154
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 17 |
| 2020 | 89 |
| 2021 | 152 |
| 2022 | 437 |
| 2023 | 733 |
| 2024 | 926 |
| 2025 | 1,195 |
| 2026 | 989 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 254 | 32.9 | 29.2 | 7,783 |
| disease progressionSignal | 318 | 12.5 | 11.2 | 3,358 |
| contusionSignal | 241 | 11.6 | 10.3 | 2,335 |
| white blood cell count decreasedSignal | 247 | 10.6 | 9.4 | 2,139 |
| platelet count decreasedSignal | 219 | 9.5 | 8.4 | 1,670 |
| anaemiaSignal | 247 | 6.0 | 5.3 | 1,034 |
| off label useSignal | 585 | 3.1 | 2.9 | 864 |
| pneumoniaSignal | 201 | 2.9 | 2.5 | 248 |
| rashSignal | 212 | 2.3 | 2.0 | 150 |
| asthenia | 154 | 1.9 | 1.6 | 66 |
| fatigue | 249 | 1.5 | 1.3 | 40 |
| diarrhoea | 185 | 1.3 | 1.2 | 15 |
| death | 211 | 1.1 | 1.0 | 3 |
| nausea | 156 | 0.9 | 0.8 | 1 |
| drug ineffective | 155 | 0.5 | 0.5 | 62 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.